Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

索拉非尼 医学 肝细胞癌 危险系数 内科学 实体瘤疗效评价标准 肝癌 肿瘤科 经导管动脉化疗栓塞 胃肠病学 随机对照试验 随机化 置信区间 肝功能 进行性疾病 化疗
作者
Masatoshi Kudo,Kazuomi Ueshima,Masafumi Ikeda,Takuji Torimura,Nobukazu Tanabe,Hiroshi Aikata,Namiki Izumi,Takahiro Yamasaki,Shunsuke Nojiri,Keisuke Hino,Hidetaka Tsumura,Teiji Kuzuya,Norio Isoda,Michihisa Moriguchi,Hajime Aino,Akio Ido,Naoto Kawabe,Kazuhiko Nakao,Yoshiyuki Wada,Sadahisa Ogasawara,Kenichi Yoshimura,Takuji Okusaka,Junji Furuse,Norihiro Kokudo,Kiwamu Okita,Philip J. Johnson,Yasuaki Arai
出处
期刊:Liver cancer [Karger Publishers]
卷期号:11 (4): 354-367 被引量:72
标识
DOI:10.1159/000522547
摘要

<b><i>Introduction:</i></b> Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034). <b><i>Methods:</i></b> Patients with unresectable HCC were randomized to a TACE plus sorafenib group (<i>N</i> = 80) or a TACE alone group (<i>N</i> = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2–3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE. <b><i>Results:</i></b> At the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607–1.223; <i>p</i> = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466–0.938; <i>p</i> = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (<i>p</i> = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria. <b><i>Conclusions:</i></b> In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
happy完成签到 ,获得积分10
3秒前
拾壹完成签到,获得积分10
11秒前
雪花完成签到,获得积分10
13秒前
清风完成签到 ,获得积分10
13秒前
雪花发布了新的文献求助10
17秒前
秀丽笑容完成签到 ,获得积分10
21秒前
江湖应助聪慧芷巧采纳,获得10
22秒前
量子星尘发布了新的文献求助10
23秒前
Rjy完成签到 ,获得积分10
29秒前
性感母蟑螂完成签到 ,获得积分10
35秒前
ruochenzu完成签到,获得积分10
37秒前
陈尹蓝完成签到 ,获得积分10
38秒前
天道酬勤完成签到,获得积分10
40秒前
42秒前
仁爱的谷南完成签到,获得积分10
42秒前
雯雯完成签到 ,获得积分10
44秒前
一路有你完成签到 ,获得积分10
44秒前
45秒前
ruochenzu发布了新的文献求助10
45秒前
47秒前
wanghao完成签到 ,获得积分10
48秒前
图图发布了新的文献求助10
48秒前
十三完成签到 ,获得积分10
48秒前
聪慧芷巧完成签到,获得积分10
49秒前
米博士完成签到,获得积分10
50秒前
研友_VZGVzn完成签到,获得积分10
51秒前
Cheung2121发布了新的文献求助30
52秒前
黄芩完成签到 ,获得积分10
53秒前
1分钟前
秋半梦完成签到,获得积分10
1分钟前
李爱国应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
搜集达人应助科研通管家采纳,获得10
1分钟前
打地鼠工人完成签到,获得积分10
1分钟前
彩色半烟完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
Ning完成签到,获得积分10
1分钟前
图图完成签到,获得积分10
1分钟前
勤奋的灯完成签到 ,获得积分10
1分钟前
ludong_0完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022